Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
1
25%
Ph phase_1
1
25%
Ph phase_4
2
50%

Phase Distribution

1

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(2)

Detailed Status

Completed2
Enrolling by invitation1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (25.0%)
Phase 31 (25.0%)
Phase 42 (50.0%)

Trials by Status

completed250%
enrolling_by_invitation125%
recruiting125%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_3

Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE

NCT07199894
enrolling_by_invitationphase_4

Bleeding Prevention With Desmopressin for Allograft Kidney Biopsies

NCT06622187
completedphase_1

Treatment of Supine Hypertension in Autonomic Failure

NCT00223717
completedphase_4

Desmopressin in Cardiac Surgery

NCT00337766

Clinical Trials (4)

Showing 4 of 4 trials
NCT07199894Phase 3

Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE

Recruiting
NCT06622187Phase 4

Bleeding Prevention With Desmopressin for Allograft Kidney Biopsies

Enrolling By Invitation
NCT00223717Phase 1

Treatment of Supine Hypertension in Autonomic Failure

Completed
NCT00337766Phase 4

Desmopressin in Cardiac Surgery

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4